Trials / Conditions / Congenital FXIII Deficiency

Congenital FXIII Deficiency

10 registered clinical trials studyying Congenital FXIII Deficiency.

Status	Trial	Sponsor	Phase
Completed	A Study of Safety and Effectiveness of NovoThirteen® (rFXIII) During Treatment of Congenital FXIII Deficiency NCT02670213	Novo Nordisk A/S	—
Completed	Use of rFXIII in Treatment of Congenital FXIII Deficiency, a Prospective Multi-centre Observational Study NCT01862367	Novo Nordisk A/S	—
Completed	Safety and Efficacy of Monthly Replacement Therapy With Recombinant Factor XIII (rFXIII) in Paediatric Subject NCT01253811	Novo Nordisk A/S	Phase 3
Completed	Safety of a Single Intravenous Dose of Recombinant Factor XIII in Children With Congenital FXIII A-subunit Def NCT01230021	Novo Nordisk A/S	Phase 3
Completed	Comparison of a Blood Clotting Drug (Recombinant Factor XIII) Produced by Two Different Manufacturers in Healt NCT01082406	Novo Nordisk A/S	Phase 1
Completed	Safety of Monthly Recombinant Factor XIII Replacement Therapy in Subjects With Congenital Factor XIII Deficien NCT00978380	Novo Nordisk A/S	Phase 3
Completed	Evaluation of Recombinant Factor XIII for Prevention of Bleeding in Patients With FXIII Inherited Deficiency NCT00713648	Novo Nordisk A/S	Phase 3
Completed	Safety and Pharmacokinetics of Recombinant Factor XIII Administration in Healthy Volunteers NCT01848002	Novo Nordisk A/S	Phase 1
Completed	Safety and Pharmacokinetics of Recombinant Factor XIII in Patients With Congenital Factor Xlll Deficiency NCT00056589	Novo Nordisk A/S	Phase 1
Completed	Safety and Pharmacokinetics of Recombinant Factor XIII in Healthy Volunteers NCT01847989	Novo Nordisk A/S	Phase 1